References

1. 1.
   KIJONKA J，VAVRA P，PENHAKER M，et al.Present results and methods of vectorcardiographic diagnostics of ischemic heart disease［J］.Comput Biol Med，2024，169：107781.
2. 2.
   TUNG L W，GROPPA E，SOLIMAN H，et al.Spatiotemporal signaling underlies progressive vascular rarefaction in myocardial infarction［J］.Nat Commun，2023，14（1）：8498.
3. 3.
   NOWBAR A N，GITTO M，HOWARD J P，et al.Mortality from ischemic heart disease［J］.Circ Cardiovasc Qual Outcomes，2019，12（6）：e005375.
4. 4.
   China Association of Chinese Medicine Cardiovascular Disease Branch.Guideline for diagnosis and treatment of coronary heart disease with stable angina pectoris［J］.J Tradit Chin Med，2019，60（21）：1880-1890.
5. 5.
   HUANG X L，LI X，YANG F W，et al.Literature study on the evolution law of traditional Chinese medicine syndrome characteristics of coronary heart disease from 1970 to 2021［J］.J Tradit Chin Med，2023，64（10）：1058-1063.
6. 6.
   LIN Z W，WU Y F，YI Q L，et al.A study on clinical literature of TCM syndrome classification of coronary heart disease ［J］.Clinl Study Trad Chin Mede，2022，14（2）：53-56.
7. 7.
   CHEN Y X，ZHANG S M，XIAO Q X，et al.Animal models for integrated differentiation of coronary heart disease and pattern［J］.J Hunan Univ Tradit Chin Med，2023，43（6）：1144-1148.
8. 8.
   GONG M.Establishment of an animal model integrating coronary heart disease and hyperglycemia syndrome and research on its biological basis［D］.Beijing：Beijing University of Traditional Chinese Medicine，2021.
9. 9.
   REN J X，LI L，YIN Y Z，et al.Intervening effects of Tongmai Yangxin pills on miniature pigs with syndrome of deficiency of both Qi and Yin in later stage of myocardial ischemia reperfusion injury［J］.Chin Tradit Herb Drugs，2018，49（7）：1612-1616.
10. 10.
    WANG P，YANG M H，LI S D，et al.Establishment of coronary heart disease and angina pectoris syndrome of cold coagulation and blood stasis animal model［J］.J Basic Chin Med，2014，20（3）：309-311.
11. 11.
    ZHU J H，LIU C，LIU H，et al.Preparation and evaluation of chronic myocardial ischemia model induced by different doses of isoproterenol in mice［J］.Lab Anim Sci，2019，36（1）：41-47.
12. 12.
    QIAN L，XU H，YUAN R，et al.Formononetin ameliorates isoproterenol induced cardiac fibrosis through improving mitochondrial dysfunction［J］.Biomed Pharmacother，2024，170：116000.
13. 13.
    YAN X，LI M，LAN P，et al.Regulation of Na⁺-K⁺-ATPase leads to disturbances of isoproterenol-induced cardiac dysfunction via interference of Ca²⁺ -dependent cardiac metabolism［J］.Clin Sci （Lond），2024，138（1）：23-42.
14. 14.
    CHANG X Y ，ZHU LP ，WANG Q J，et al.Protective effects of salidroside on myocardial ischemia induced by isoproteronol in mice［J］.Pharmacol Clin Chin Mater Med，2016，32（2）：67-70.
15. 15.
    ZHANG M Q ，CUI S，LIANG W L，et al.Effect of Yangxin Shengmai granules on myocardial ischemia and anxiety like behaviors induced by isoproterenol in mice［J］.Cent South Pharm，2022，20（7）：1521-1526.
16. 16.
    YANG M，HU S Y，LI L，et al.Chinese medical syndrome and nature of isoproterenol-induced chronic heart failure mice based on syndrome determination by formulas［J］.Pharmacol Clin Chin Mater Med，2024，40（2）：101-108.
17. 17.
    REN J G，LIU J X，WEI J H.Pharmacology of combination of disease and syndrome：strategies and methods of pharmacology of Chinese medicine［J］.Chin J Chin Mater Med，2021，46（19）：4922-4929.
18. 18.
    LI L ，LIU J X ，REN J G，et al.Research status and perspective of animal models in research and development traditional Chinese medicine［J］.Chin J Comp Med，2022，32（1）：104-110.
19. 19.
    GAO Y X，ZHANG Q Y，PENG J Q，et al.Establishment and evaluation of animal model of acute myocardial infarction with syndrome of Qi and Yin deficiency ［J］.Chin J Exp Tradit Med Form，2024，30（4）：134-142.
20. 20.
    YUE J，XU W，XIANG L，et al.Continuous exposure to isoprenaline reduced myotube size by delaying myoblast differentiation and fusion through the NFAT-MEF2C signaling pathway［J］.Sci Rep，2023，13（1）：436.
21. 21.
    DING S，GAO C J，LU F，et al.Two preparation methods of Qi and Yin deficiency syndrome mice models［J］.J Tradit Chin Med，2023，64（4）：401-409.
22. 22.
    GAO J M，HU B，SHEN E.Echocardiography in mice：procedures and standardization［J］.Chin J Med Ultrasound（Electron Ed），2020，17（1）：85-89.
23. 23.
    HUANG C J，WEBB H E，ZOURDOS M C，et al.Cardiovascular reactivity，stress，and physical activity［J］.Front Physiol，2013，4：314.
24. 24.
    NEF H M，MÖLLMANN H，AKASHI Y J，et al.Mechanisms of stress （Takotsubo） cardiomyopathy［J］.Nat Rev Cardiol，2010，7（4）：187-193.
25. 25.
    XIE Y L，ZHANG B.Effects of Angelica sinensis volatile oil on depressive behavior in mice［J］.Mod Food Sci Technol，2024，40（3）：9-17.
26. 26.
    LI J，ZHONG S J，KUANG H F，et al.Pathogenesis of metabolic remodeling of energy substrate based on theory of deficient Qi stagnation and progress of Chinese medicine intervention［J］.Chin J Exp Tradit Med Form，2023，29（17）：195-202.
27. 27.
    ZHANG C Z，WANG T F.Research progress on the relationship between antagonistic metabolic regulation of cAMP and cGMP and traditional Chinese medicine syndromes［J］.J Beijing Univ Tradit Chin Med，1999，6：51-53.
28. 28.
    GOLDBERG N D，HADDOX M K，ZEILIG C E，et al.Cyclic GMP，cyclic AMP，and the Yin Yang hypothesis of biologic regulation［J］.J Invest Dermatol，1976，67（5）：641-645.
29. 29.
    ZHANG Y X，WANG X，LIU B，et al.Preparation of animal model of type 2 diabetes with Qi-Yin deficiency syndrome and establishment of evaluation index［J］.Acta Lab Anim Sci Sin，2021，29（2）：219-229.
30. 30.
    TANG J，JILA S，LUO T，et al.C3/C3aR inhibition alleviates GMH-IVH-induced hydrocephalus by preventing microglia-astrocyte interactions in neonatal rats［J］.Neuropharmacology，2022，205：108927.
31. 31.
    TANG Y J，GUO H P，ZOU M S，et al.Mechanism of Chaishao Kaiyu decoction in ameliorating hippocampal neuroinflammation in depressed rats based on complement component C3/C3aR pathway［J］.Chin J Chin Mater Med，2025，50（1）：1-9.
32. 32.
    GUO L L，LIU Y，CHEN Y W，et al.Effect of Tiepi Fengdou granules on cyclic nucleotide-endocrine system-immune system of mice with Qi and Yin deficiency［J］.World Chin Med，2023，18（1）：20-26.
33. 33.
    LI C，LIU D.The levels of serum complement C3，C4 and HDL-C in patients with coronary heart disease［J］.Chin J Heart Heart Rhythm （Electronic Edition），2018，6（2）：68-70.
34. 34.
    SAUTER R J，SAUTER M，REIS E S，et al.Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis［J］.Circulation，2018，138（16）：1720-1735.
35. 35.
    SUBRAMANIAM S，JURK K，HOBOHM L，et al.Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development［J］.Blood，2017，129（16）：2291-2302.
36. 36.
    REN J，TSILAFAKIS K，CHEN L，et al.Crosstalk between coagulation and complement activation promotes cardiac dysfunction in arrhythmogenic right ventricular cardiomyopathy［J］.Theranostics，2021，11（12）：5939-5954.
37. 37.
    CHENG L L，LI Z L，FU Q，et al.Effect of C5-siRNA silencing receptor C5 on myocardial ischemia injury in rats［J］.J South Med Univ，2010，30（6）：1486-1488.
38. 38.
    GAWARGI F I，MISHRA P K.Regulation of cardiac ferroptosis in diabetic human heart failure：Uncovering molecular pathways and key targets［J］.Cell Death Discov，2024，10（1）：268.
39. 39.
    CHEN Y J.Effect of Yiqi Yangyin Qingre recipe on iron load in patients with type 2 diabetes［D］.Nanning：Guangxi University of Chinese Medicine，2021.
40. 40.
    YU F，WANG Z，ZHANG Z，et al.Biosynthesis，acquisition，regulation，and upcycling of heme：Recent advances［J］.Crit Rev Biotechnol，2024，44（7）：1422-1438.
41. 41.
    FANG X，WANG H，HAN D，et al.Ferroptosis as a target for protection against cardiomyopathy［J］.Proc Natl Acad Sci USA，2019，116（7）：2672-2680.